Blog
RSS FeedPosted by Michael Wonder on 20 Jul 2020
HLS Therapeutics welcomes both CADTH's recommendation to reimburse Vascepa (icosapent ethyl) for patients with established cardiovascular disease and PMPRB's notification on its introductory price
20 July 2020 - CADTH recommends Vascepa be reimbursed for patients with established cardiovascular disease under certain conditions. ...
Posted by Michael Wonder on 20 Jul 2020
CADTH publishes final recommendation for Stelara
20 July 2020 - CADTH has completed its assessment of ustekinumab by intravenous injection for the treatment of adult patients ...
Posted by Michael Wonder on 18 Jul 2020
'Heartbreaking': Alberta families describe waiting for life-changing drug to be made available in Canada
17 July 2020 - More families are hoping a one-time treatment option for a rare condition will be made available ...
Posted by Michael Wonder on 14 Jul 2020
Dupixent (dupilumab) receives positive recommendation from INESSS for the treatment of moderate to severe atopic dermatitis in adolescents
14 July 2020 - The Institut national d'excellence en santé et en services sociaux (INESSS) recommends extending existing coverage in Quebec ...
Posted by Michael Wonder on 14 Jul 2020
PMPRB changes within scope of Patent Act, rules federal court in judicial review
13 July 2020 - The Federal Court has upheld reforms to the Patented Medicines Pricing Review Board that updated the ...
Posted by Michael Wonder on 06 Jul 2020
Canadians demand access to ‘miracle’ cystic fibrosis drug already approved in U.S. and U.K
6 July 2020 - Montreal’s Chelsea Gagnon may look like a healthy 31-year-old woman at first glance, but every single ...
Posted by Michael Wonder on 05 Jul 2020
Clock ticking on Edmonton family's hope for $2.8 million drug treatment for toddler son
3 July 2020 - Family hoping Alberta Health will pay for new drug that must be administered by mid-July. ...
Posted by Michael Wonder on 30 Jun 2020
Canada federal court dismisses drug makers' plea challenging drug price rules
30 June 2020 - The federal court of Canada on Monday dismissed a plea by drug makers challenging the Canadian ...
Posted by Michael Wonder on 29 Jun 2020
IMC responds to Federal Court decision regarding PMPRB regulatory changes
29 June 2020 - Innovative Medicines Canada released the following statement today in response to the Federal Court of Canada’s ...
Posted by Michael Wonder on 25 Jun 2020
Consultation on CADTH’s drug reimbursement review procedures
25 June 2020 - CADTH is inviting stakeholder feedback on a revised procedure for its drug reimbursement review processes (i.e., pan-Canadian ...
Posted by Michael Wonder on 25 Jun 2020
Sandoz Canada launches the biosimilars generation
25 June 2020 - Campaign provides needed, fact-based, information for patients, healthcare providers and Canadians about biosimilar medicines in Canada. ...
Posted by Michael Wonder on 22 Jun 2020
PMPRB publishes new draft guidelines, launches 30 day consultation
22 June 2020 - As reported earlier this month, the Patented Medicine Prices Review Board has published a new draft ...
Posted by Michael Wonder on 20 Jun 2020
This drug can treat 90 per cent of cystic fibrosis patients, but it's not available in Canada
19 June 2020 - Struggling to breathe is one of the main symptoms of the novel coronavirus that has recently ...
Posted by Michael Wonder on 18 Jun 2020
Vertex and Canada hold talks over cystic fibrosis drug, but a deal for newer medicine remains out of reach
18 June 2020 - The icy relationship between Vertex Pharmaceuticals and the Canadian government is showing signs of thawing a ...
Posted by Michael Wonder on 15 Jun 2020
Rising costs explain why Canada is switching to biosimilars
15 June 2020 - Following in the footsteps of British Columbia, other Canadian provinces are working to implement their own biosimilars ...